Alto Neuroscience | BiotechTV

top of page

Alto Neuroscience's CEO on today's $128.6 million NYSE IPO

Feb 2

Company News

Alto Neuroscience's CEO on today's $128.6 million NYSE IPO

Amit Etkin describes Alto's approach to tyring to bring precision medicine to psychiatry.

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

Dec 4, 2023

Company News

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

Amit Etkin says that psychiatric conditions have been treated too broadly in the past.

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh